{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8"},{"groupId":"OG001","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1865"},{"groupId":"OG001","value":"708"}],"units":"Participants"}],"description":"The percentage of participants who died from any cause was reported during the safety follow-up period.","groups":[{"description":"Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe.","id":"OG000","title":"Cohort A: SC Herceptin by Needle/Syringe"},{"description":"Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was administered from a pre-filled SID. The first administration was performed by an HCP. Subsequent doses were self-administered by participants who were willing and judged competent by the HCP.","id":"OG001","title":"Cohort B: SC Herceptin by SID"}],"paramType":"NUMBER","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From Baseline to Time of Event, Safety Follow-Up Period (Up to 6 Years)","title":"Percentage of Participants Who Died During the Safety Follow-up Period","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}